drugset
drugset / Trial / NCT04767035

Relative Bioavailability Study of MELT-100, IV Midazolam, and IV Ketamine

NCT04767035 ↗

Phase 1 Completed 25 enrolled Melt Pharmaceuticals Worldwide Clinical Trials · collab
RandomizedCrossoverOpen-labelTreatment

Summary

A Pivotal Phase 1, Randomized, Single-Dose, 4-Period, Crossover Relative Bioavailability Study of MELT-100, IV Midazolam, and IV Ketamine under Fasted Conditions in Healthy Volunteers

Timeline

Start
2020-12-01
Primary completion
2021-01-14
Completion
2021-01-14

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ketamine Small molecule 18 mg Other
Comparator Ketamine Small molecule 25 mg Other
Comparator Midazolam Small molecule 3 mg Other
Comparator Midazolam Small molecule 3.5 mg Other

Indications

No indication recorded.